Thank you for sharing your excitement about CLDX. What do you think about IMUC and NWBO going into ASH presentations next week?
IMUC gets good pr on the EU part.
What's happening this weekend and Monday is ASH. MM driving it down today to load up, then let if fly on Monday. Same thing going on with other ASH stocks IMGN and SGMO.
I don't see systemic dumping of SGen. A trade of 49,700 shares this morning may have disturbed some smaller investors, as today's subsequent trades mostly range from 100 to 300 shares. Perhaps the big investor sold some SGen at the end of Feb at $55, and afterwards accumulated. He or she is now facing a whopping tax obligation and decided to shed shares accumulated in the high 40's.
By the end of today SGen pps is likely to be up a bit.
I asume after data is shown at ash, the price will go up con the news. Why would BB and RA bought shates this Q?
Sentiment: Strong Buy
or a take under/low premium deal. SEGN may be fully valued and BB's may want to cash in. Since I own IMGN, I am rooting for both to eventually be acquired and higher prices, but the relative valuations seem out of line IMO.
This stock always is manipulated prior to and often after good news is expected. Every indication has been that SGEN will generate positive news on many fronts during ASH. Always best to keep focused on the long-term with this company and stock.
Most likely OPEX related (Friday). Also year end tax loss harvesting. Next week should be interesting. Any indication that Aethera I (also LIV I update) is doing well and it blows off the cap otherways it is same old lock until then.
HAMPTON, N.J., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (CLDX) today announced that it has initiated an open-label Phase 2 study of glembatumumab vedotin (CDX-011) in patients with unresectable Stage III or IV melanoma. Glembatumumab vedotin is a fully-human monoclonal antibody-drug conjugate (ADC) that targets glycoprotein NMB (gpNMB), a protein overexpressed by multiple tumor types, including metastatic melanoma where approximately 85% of patients overexpress the marker. Overexpression of gpNMB has been shown to promote the invasion and metastasis of cancer and has been associated with poor clinical outcome. The study is expected to include up to 10 sites in the United States and will enroll approximately 60 patients. Glembatumumab vedotin was previously evaluated in a Phase 1/2 study in patients with unresectable stage III or stage IV melanoma, a Phase 1/2 study in advanced breast cancer, a Phase 2 study in advanced breast cancer (the EMERGE study) and is currently being evaluated in patients with metastatic triple negative breast cancers that overexpress gpNMB in the METRIC Study.
The value is not where you think it is. I am most interested in the efficacy blockbuster potential for SGN-LIV1A. There is not specific indications only preclinical but the data is robust. Also i am high on SGN-CD33A . That form of luekemia potentially to be treated by SGN-CD33A is close to 18k patients in US I am also interested in the following compound SEA-CD40 . Look your value will not come from a conference or anything in Phase 3 currently Your value and PPS push will come from Phase 2 study data from one of the 3 compounds i mentioned. I think 2015 will be much like 2014 . Look towards 2016 and 2017 where i anticipate PPS will reach 75 if all goes well.
Cancer treatments are almost always brutal (been there and done it). However is there really a choice considering the alternative?
If you're drowning and the only rope available to potentially save yourself is intertwined with glass chards and blades you grab it you bleed and you keep grabbing and hanging to it until you either get to dry land or bleed to death trying.
Good for those who can continue. I am not sure as to why they can't lower the dose. About the same numbers get PN from Adcetris R-CHOP, but not enough to discontinue. The dose of Adcetris is lowered instead.